언어 선택

Plasma Kallikrein/KLKB1

Plasma Kallikrein/KLKB1 분자 정보

영어 이름	Plasma kallikrein	시판 약물 수	4
임상 약물 수	13	표적 별명	EC:3.4.21.34，EC 3.4.21，Fletcher factor，Plasma prekallikrein，KLKB1，Kallikrein B1，Kallikrein B， Plasma (Fletcher Factor) 1，Kininogenin，KLK3，PKK，Plasma Kallikrein，EC 3.4.21.34，PKKD，PPK，PKal，pKAL
최고 연구 개발 단계	Approved

영어 이름	Plasma kallikrein
표적 별명	EC:3.4.21.34，EC 3.4.21，Fletcher factor，Plasma prekallikrein，KLKB1，Kallikrein B1，Kallikrein B， Plasma (Fletcher Factor) 1，Kininogenin，KLK3，PKK，Plasma Kallikrein，EC 3.4.21.34，PKKD，PPK，PKal，pKAL
시판 약물 수	4
임상 약물 수	13
최고 연구 개발 단계	Approved

Plasma Kallikrein/KLKB1 제품 목록

속성
Protein (3)
제품 라이브러리
온라인 (3)
종
Mouse (1)Human (1)Cynomolgus (1)
태그
His Tag (3)
마커
Unconjugated (3)

제품 번호	종	발현 시스템	제품 설명
KL1-H52H9	Human	HEK293	Human Plasma Kallikrein / KLKB1 Protein, His Tag (Pro-form, MALS verified)
KL1-M52H9	Mouse	HEK293	Mouse Plasma Kallikrein / KLKB1 Protein, His Tag (active enzyme)
KL1-C52H3	Cynomolgus	HEK293	Cynomolgus Plasma Kallikrein / KLKB1 Protein, His Tag (active enzyme, MALS verified)

총 수량3

Plasma Kallikrein/KLKB1분자 배경

Human Plasma Kallikrein, a serine protease, is synthesized in the liver and circulates in the plasma by binding to high molecular weight (HMW) kininogen or as a free zymogen. The enzyme cleaves Lys-Arg and Arg-Ser bonds. It activates, in a reciprocal reaction, factor XII after its binding to a negatively charged surface. It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into renin.

Plasma Kallikrein/KLKB1분자 별명

Fletcher factor,kallikrein B, plasma (Fletcher factor) 1,kininogenin,KLK3 plasma kallikrein,KLKB1,plasma kallikrein heavy chain,plasma kallikrein light chain,Plasma Kallikrein,Plasma Prekallikrein,PPK,KLKB1

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Navenibart	QLS-215; STAR-0215	Phase 3 Clinical	Quellis Biosciences Inc	Angioedemas, Hereditary	상세
ADX-324	ADX-324; ADX324	Phase 3 Clinical	ADARx Pharmaceuticals Inc	Angioedemas, Hereditary	상세
Lonvoguran Ziclumeran	NTLA-2002	Phase 3 Clinical	Intellia Therapeutics Inc	Angioedemas, Hereditary	상세
THR-149	TG-758; THR-149	Phase 2 Clinical	Bicycle Therapeutics, Thrombogenics Inc	Diabetes Mellitus; Diabetic macular oedema; Diabetic Retinopathy	상세
BW-20805	BW-20805; BW20805	Phase 2 Clinical	Hangzhou Bolin Pharmaceutical Technology Co Ltd	Angioedemas, Hereditary	상세
MDPK-67b	DM-107; MDPK-67; MDPK-67b; MDKP 67b; RIK-7	Phase 1 Clinical	Med Discovery	Prostatic Neoplasms	상세
MSB-03	MSB-03	Phase 1 Clinical	MatriSys Bioscience Inc	Rosacea	상세
Avoralstat	BCX-V; BCX-4161	Phase 1 Clinical	Biocryst Pharmaceuticals Inc	Angioedemas, Hereditary; Diabetic macular oedema	상세
ADX-324(Tenacia)	ADX324; ADX-324	Phase 1 Clinical	Yuanyi Biotechnology (Shanghai) Co., Ltd.	Angioedemas, Hereditary	상세
ZKLJ-02		Phase 1 Clinical	Kunming Longjin Pharmaceutical Co Ltd	Cardiovascular Diseases; Ischemic Stroke; Nervous System Diseases; Stroke	상세
ATN-249	ATN-249	Phase 1 Clinical	Attune Pharmaceuticals	Angioedemas, Hereditary	상세
BI-Z		Clinical	Boehringer Ingelheim Pharma Gmbh & Co Kg	Wet Macular Degeneration	상세
mRNA encoded Cas9 targeting human KLKB 1 gene therapy (Pharma Gateway)		Clinical	Pharma Gateway AB	Angioedemas, Hereditary	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Lanadelumab	2372V1TKXK (UNII code); X124-G01; SHP-643; DX-2930; TAK-743	Approved	Dyax Pharma	Takhzyro, 达泽优	United States	Angioedemas, Hereditary	Dyax Corp	2018-08-23	Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Hereditary Autoinflammatory Diseases; Lung Injury	상세
Berotralstat	BCX-7353	Approved	Biocryst Pharmaceuticals Inc	ORLADEYO	United States	Angioedemas, Hereditary	Biocryst Pharmaceuticals Inc	2020-12-03	Angioedemas, Hereditary	상세
Ecallantide	DX-88; EPI-KAL2; FOV-2302; CB-500929	Approved	Dyax Pharma	Kalbitor	United States	Angioedema	Dyax Corp	2009-12-01	Angioedema; Angioedemas, Hereditary; Blood Loss, Surgical; Hemorrhage; Hereditary Angioedema Types I and II; Macular Edema; Retinal Vein Occlusion	상세
Sebetralstat	KVD-900	Approved	Vantia Therapeutics Ltd.	Ekterly	United States	Angioedemas, Hereditary	Kalvista Pharmaceuticals Ltd, Kalvista Pharmaceuticals Inc	2025-07-03	Angioedemas, Hereditary	상세